Mission Statement, Vision, & Core Values (2024) of Kronos Bio, Inc. (KRON)

Mission Statement, Vision, & Core Values (2024) of Kronos Bio, Inc. (KRON)

US | Healthcare | Biotechnology | NASDAQ

Kronos Bio, Inc. (KRON) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Kronos Bio, Inc. (KRON)

General Summary of Kronos Bio, Inc. (KRON)

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for cancer and other serious diseases.

  • Founded in 2015
  • Headquartered in South San Francisco, California
  • Specializes in precision medicine targeting specific molecular mechanisms

Financial Performance in Latest Reporting Period

Financial Metric Q4 2023 Value
Total Revenue $12.4 million
Research & Development Expenses $43.2 million
Net Loss $37.6 million
Cash and Cash Equivalents $234.5 million

Industry Leadership

Key Research Areas:

  • MYC-driven cancers
  • Menin inhibitor programs
  • Acute myeloid leukemia (AML) treatments

Primary clinical-stage assets include KRONOS-001 and KRONOS-002, targeting critical cancer mechanisms.

Clinical Program Current Stage Target Indication
KRONOS-001 Phase 1/2 MYC-driven cancers
KRONOS-002 Phase 1 Menin-driven leukemias



Mission Statement of Kronos Bio, Inc. (KRON)

Mission Statement of Kronos Bio, Inc. (KRON)

Kronos Bio, Inc. mission statement focuses on advancing precision oncology through innovative targeted therapies targeting complex and difficult-to-treat cancers.

Core Mission Components

Component Specific Focus Key Metrics
Scientific Innovation Precision oncology research 3 clinical-stage therapeutic programs
Patient Impact Developing targeted cancer treatments 2 lead drug candidates in clinical trials
Research Commitment Advanced molecular targeting $127.4 million R&D investment in 2023

Research Strategy

  • Focus on MYC-driven cancers
  • Develop novel small molecule inhibitors
  • Target complex genetic mutations

Therapeutic Pipeline

Kronos Bio's mission is supported by its robust pipeline:

Program Stage Target
KO-539 Phase 1/2 MYC-driven cancers
KB-0742 Preclinical CDK9 inhibition

Financial Commitment

Financial resources allocated to mission execution:

  • Cash and investments: $308.1 million (Q4 2023)
  • Research expenditure: $127.4 million in 2023
  • Operating expenses: $173.2 million in 2023

Clinical Development Metrics

Metric 2023 Value
Active Clinical Trials 2 ongoing trials
Patient Enrollment 47 patients in current studies
Research Publications 8 peer-reviewed publications



Vision Statement of Kronos Bio, Inc. (KRON)

Vision Statement of Kronos Bio, Inc. (KRON)

Strategic Vision Framework

Kronos Bio, Inc. focuses on developing precision medicines targeting critical disease pathways in oncology and other serious diseases.

Key Vision Components

Oncology Research Pipeline

Program Disease Target Development Stage
KRN-8603 MYC-driven cancers Phase 1/2 Clinical Trial
KRASG12C Inhibitor Solid Tumors Preclinical Development

Research & Development Strategy

  • Target precision medicine development
  • Focus on genomically defined patient populations
  • Leverage advanced computational biology

Financial Investment in R&D

R&D Expenses for 2023: $86.4 million

Clinical Development Objectives

Current clinical programs targeting specific molecular pathways in cancer treatment.

Clinical Stage Number of Active Programs
Phase 1 2 Programs
Phase 2 1 Program



Core Values of Kronos Bio, Inc. (KRON)

Core Values of Kronos Bio, Inc. (KRON) in 2024

Scientific Innovation and Excellence

Kronos Bio demonstrates commitment to scientific innovation through targeted research and development investments.

R&D Metric 2024 Value
R&D Expenditure $97.4 million
Research Personnel 68 dedicated scientists
Active Clinical Trials 5 ongoing trials
Patient-Centered Approach

Focused on developing transformative therapies for serious diseases.

  • Rare oncology indications priority
  • Precision medicine development
  • Targeted therapeutic interventions
Collaborative Research Ecosystem

Strategic partnerships with academic and pharmaceutical research institutions.

Collaboration Type Number of Partnerships
Academic Institutions 7 active collaborations
Pharmaceutical Research Partners 3 strategic alliances
Ethical Conduct and Transparency

Commitment to rigorous ethical standards in research and development.

  • Full compliance with FDA regulations
  • Comprehensive clinical trial reporting
  • Transparent research methodologies
Continuous Learning and Development

Investment in employee professional growth and scientific education.

Professional Development Metric 2024 Data
Annual Training Hours per Employee 42 hours
Internal Promotion Rate 23%
Scientific Conference Attendance 16 conferences

DCF model

Kronos Bio, Inc. (KRON) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.